Skip to content
TrialScanner

NCT04516278

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Phase 3CompletedOTLKLead

Registry record

Lead sponsor
Outlook Therapeutics, Inc.
Conditions
Age-related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration; BRVO - Branch Retinal Vein Occlusion; Diabetic Macular Edema
Primary completion
Feb 10, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04516278 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04516278: A 3-month Study to Assess... | TrialScanner